Liquidia (NASDAQ:LQDA) CFO Sells $5,595,114.60 in Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 139,390 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $40.14, for a total transaction of $5,595,114.60. Following the transaction, the chief financial officer directly owned 353,356 shares in the company, valued at approximately $14,183,709.84. The trade was a 28.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Kaseta also recently made the following trade(s):

• On Tuesday, April 14th, Michael Kaseta sold 3,000 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00.
• On Monday, April 13th, Michael Kaseta sold 18,958 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total transaction of $727,418.46.
• On Friday, April 10th, Michael Kaseta sold 23,821 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $956,174.94.
• On Thursday, April 9th, Michael Kaseta sold 133,789 shares of Liquidia stock. The stock was sold at an average price of $40.24, for a total transaction of $5,383,669.36.

Liquidia Stock Up 3.2%

Shares of NASDAQ:LQDA traded up $1.28 during midday trading on Thursday, reaching $41.40. The company’s stock had a trading volume of 1,184,168 shares, compared to its average volume of 983,955. The firm has a 50 day moving average of $36.63 and a 200-day moving average of $33.14. The firm has a market capitalization of $3.65 billion, a P/E ratio of -49.88 and a beta of 0.45. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $46.67.

Liquidia (NASDAQ:LQDA) last released its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. Liquidia’s quarterly revenue was up 3072.4% compared to the same quarter last year. On average, research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LQDA. Jefferies Financial Group upped their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. Needham & Company LLC upped their target price on shares of Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Wells Fargo & Company upped their target price on shares of Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a research note on Monday, March 23rd. Finally, BTIG Research upped their target price on shares of Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and an average price target of $43.44.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new stake in Liquidia in the 4th quarter worth approximately $3,148,000. Invesco Ltd. increased its holdings in Liquidia by 428.3% in the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock worth $14,507,000 after acquiring an additional 341,009 shares in the last quarter. XTX Topco Ltd purchased a new stake in Liquidia in the 4th quarter worth approximately $1,214,000. nVerses Capital LLC purchased a new stake in Liquidia in the 4th quarter worth approximately $335,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in Liquidia in the 4th quarter worth approximately $3,107,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).